The historical rank and industry rank for Sun Pharma Advanced Research Co's Pretax Margin % or its related term are showing as below:
NSE:SPARC'
s Pretax Margin % Range Over the Past 10 Years
Min: -512.05 Med: -120.71 Max: 82.64
Current: 82.64
NSE:SPARC's Pretax Margin % is ranked better than 98.53% of 954
companies
in the Drug Manufacturers industry
Industry Median: 7.295
vs NSE:SPARC: 82.64
Sun Pharma Advanced Research Co (NSE:SPARC) Pretax Margin % Explanation
The pretax margin, as know as pretax profit margin, is widely used to measure the operating efficiency of a company before deducting taxes.
The pretax margin is sometimes preferred over the net margin as tax expenditures can make profitability comparisons between companies misleading.
It is a useful tool to compare companies operating in the same sector and less effective when comparing companies from other sectors as each industry generally has different operating expenses and sales patterns.
The long term trend of the pretax margin is a good indicator of the competitiveness and health of the business.
Sun Pharma Advanced Research Co Pretax Margin % Related Terms
Sun Pharma Advanced Research Co Pretax Margin % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Sun Pharma Advanced Research Co Pretax Margin % Chart
NSE:SPARC vs ZTS, UTHR: Pretax Margin % Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Sun Pharma Advanced Research Co's Pretax Margin %, along with its competitors' market caps and Pretax Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Sun Pharma Advanced Research Co Pretax Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Sun Pharma Advanced Research Co's Pretax Margin % distribution charts can be found below:
* The bar in red indicates where Sun Pharma Advanced Research Co's Pretax Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Sun Pharma Advanced Research Co (NSE:SPARC) has a Pretax Margin % of 95.02% as of Mar. 2026. Pre-Tax margin is the ratio of total pre-tax income to net sales. View historical data on Sun Pharma Advanced Research Co and its competitors. According to the industry distribution chart, Sun Pharma Advanced Research Co ranks #14 out of 954 companies in the Drug Manufacturers industry, placing it in the top 1.5%.
Is Sun Pharma Advanced Research Co's Pretax Margin % too high?
Sun Pharma Advanced Research Co's current Pretax Margin % is 95.02%. The Drug Manufacturers industry median Pretax Margin % is 7.30. Sun Pharma Advanced Research Co's value of 95.02% is 1202.5% above this industry median. Based on the distribution chart, Sun Pharma Advanced Research Co ranks #14 out of 954 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Sun Pharma Advanced Research Co has a GF Score™ of 61/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Sun Pharma Advanced Research Co's Pretax Margin % compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Sun Pharma Advanced Research Co ranks #14 out of 954 companies for Pretax Margin %. This places Sun Pharma Advanced Research Co in the top 2% of its industry — outperforming the majority of peers. The industry median Pretax Margin % is 7.30. Sun Pharma Advanced Research Co's value of 95.02% is 1202.5% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Pretax Margin % for a Drug Manufacturers company?
The median Pretax Margin % among Drug Manufacturers companies is 7.30, based on 954 companies in the industry. Companies in the top quartile (top 25%) have a Pretax Margin % significantly above this median, while those in the bottom quartile fall well below. However, Pretax Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Sun Pharma Advanced Research Co's current Pretax Margin % of 95.02% is 1202.5% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Pretax Margin % mean?
A high Pretax Margin % can signal that a stock is expensive relative to its fundamentals. Pre-Tax margin is the ratio of total pre-tax income to net sales. View historical data on Sun Pharma Advanced Research Co and its competitors. For the Drug Manufacturers industry, the median Pretax Margin % is 7.30 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Sun Pharma Advanced Research Co's current Pretax Margin % is 95.02%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sun Pharma Advanced Research Co stock overvalued right now?
Based on GuruFocus' analysis, Sun Pharma Advanced Research Co (NSE:SPARC) is currently considered Possible Value Trap. The stock's GF Value™ is ₹4,504.88, compared to a current price of ₹239.37 — trading 94.7% below its estimated fair value. The current Pretax Margin % is 95.02% and 1202.5% above the Drug Manufacturers industry median of 7.30. Sun Pharma Advanced Research Co's overall GF Score™ is 61/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Pretax Margin % calculated?
Pretax Margin % is calculated from a company's financial statements. For Sun Pharma Advanced Research Co (NSE:SPARC), the current Pretax Margin % is 95.02% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Sun Pharma Advanced Research Co (NSE:SPARC) Overvalued in 2026?
Based on GuruFocus' analysis, Sun Pharma Advanced Research Co stock appears to be undervalued.
The current stock price of ₹239.37 is trading 94.7% below its estimated GF Value™ of ₹4,504.88.
GuruFocus considers Sun Pharma Advanced Research Co to be Possible Value Trap.
Key valuation signals for NSE:SPARC:
Pretax Margin %: 95.02%
GF Value™: ₹4,504.88 vs. price of ₹239.37 (94.7% below fair value)
Industry Position: 1202.5% above the Drug Manufacturers median (#14 of 954)
No single metric tells the full story. See the NSE:SPARC stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Sun Pharma Advanced Research Co Business Description
Sun Pharma Advanced Research Co Ltd is an Indian specialty and generic drug manufacturing company. The company has identified pharmaceuticals research and development as its only reportable segment. The company is focused on drug discovery in focused therapy areas such as cancer and anti-inflammatory treatments. The company considers merger and acquisition investment as a potential component of its operational growth plan for expanding its research, development, manufacturing, and marketing capabilities. It derives maximum revenue from India and also has its presence in other countries.
61GF Score
Get the complete analysis for NSE:SPARC
Pretax Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:SPARC has been successfully added to your 
